Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Mastercard

These top stocks are on a winning streak and have the businesses to keep it going.

2 Winning Growth Stocks That Are Screaming Buys Right Now

Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list of drugs in short supply.

Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List

Hims & Hers stock is undervalued at 25x forward free cash flow, presenting a tremendous bargain given its strong fundamentals and growth potential. Despite volatility and marketing spend concerns, Hims & Hers boasts over 2 million paying subscribers, with significant growth expected organically, not just from GLP1 products. With no debt and over $230 million in cash, Hims & Hers is financially robust and profitable, projecting $220 million EBITDA and $170 million free cash flow in 2025.

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in the last 12 months and by 112% this year, outperforming the benchmark Nasdaq 100 and S&P 500 indices and other companies in the healthcare industry.

Is the soaring Hims & Hers stock a good investment?

CRISPR Therapeutics

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Hims & Hers stock is currently in the middle of a deep drawdown, with HIMS stock nearly 35% off of its recent highs. However, the telehealth platform company remains a fundamentally sound business and is getting stronger by broadening its diversified weight loss offering through the addition of compounded GLP-1s. As of Q2, Hims & Hers is delivering top-line hypergrowth, and turning into an FCF machine.

Hims & Hers: The Gift That Keeps On Giving

Hims & Hers is a fantastic value despite its high 'on-the-surface' P/E ratio and valuation metrics. The company's subscription-based model in healthcare, targeting chronic conditions, ensures recurring revenue and high customer retention, leading to consistent revenue growth. High gross margins lead to incredible operating leverage, and we see net income increasing from $15 million to more than $600 million in the next 24 months.

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.

Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts

CrowdStrike

Alphabet

While it is no secret that assets in the stock market can offer substantial profits to skillful investors and traders, it is sometimes difficult to discern which stocks are better than others in this regard and which could provide an income of, say, $10,000 from investing a mere $1,000 in them.

Where to put $1,000 in stocks to make $10k in 2025

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.

Hims & Hers offers compounded Wegovy for $99 a month to select professions

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have.

Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders

Buying a new pharmacy will allow Hims & Hers to expand into new markets.

Hims & Hers Acquisition: How Innovation Will Flourish

This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.

Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity

Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.

Hims & Hers Stock Pops After Massive Acquisition

Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.

Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?

Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.

Is Hims & Hers Health the Next Teladoc?

NexGen Energy

Wayfair

Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.

Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long

Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.

Is Hims & Hers Health Stock a Buy?

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?

AbbVie

UnitedHealth Group

Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.

Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever

Eli Lilly

Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.

Has Eli Lilly Destroyed Hims & Hers Upside?

Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.

News for Hims & Hers Health Stock (HIMS)